Tactiva Therapeutics

A next generation adaptive cell therapy (ACT) company that is developing a TCR (T-cell receptor) therapy which uniquely combines CD4 and CD8 systems in order to produce a more clinically relevant therapeutic. The T cells derive from a patient’s own cells and are re-programmed to recognize, attack and destroy cancer cells. Lead program, DEACT (Dual Enhanced Adoptive Cell Therapy) targets NY-EOS-1 in ovarian cancers and other solid tumors and has IND clearance in US